DAX25.135 +0,1%Est506.278 -0,1%MSCI World4.343 -0,1%Top 10 Crypto8,3900 +4,4%Nas26.207 +1,3%Bitcoin56.299 +1,8%Euro1,1437 +0,1%Öl76,20 +0,4%Gold4.108 -0,3%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 SpaceX A42D4F NVIDIA 918422 Volkswagen (VW) vz. 766403 Infineon 623100 SAP 716460 Deutsche Telekom 555750 Siemens Energy ENER6Y Micron Technology 869020 Bayer BAY001 Lufthansa 823212 DEUTZ 630500 TKMS thyssenkrupp Marine Systems TKMS00 Allianz 840400 Deutsche Bank 514000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Iran-Krieg im Blick: DAX stabil -- SK hynix vor NASDAQ-Start -- VW: Modellpalette soll um die Hälfte schrumpfen -- Apple, Oracle, SpaceX, Tesla, Bayer, Siemens Energy, Meta im Fokus
Top News
Digitalwährungen im Fokus: So bewegen sich Bitcoin & Co. am Mittag Digitalwährungen im Fokus: So bewegen sich Bitcoin & Co. am Mittag
Apple-Aktie: Hedgeye sieht 23 Prozent Abwärtspotenzial trotz KI-Übernahmeplan Apple-Aktie: Hedgeye sieht 23 Prozent Abwärtspotenzial trotz KI-Übernahmeplan
Suche...
Jetzt kostenlos
bei finanzen.net anmelden
Watchlists & Musterdepots Tools & integriertes Trading Newsletter, Trading-Desk uvm.
Schon einen Account? Anmelden
Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Jazz Pharmaceuticals Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
212,70 EUR -3,50 EUR -1,62 %
STU
246,99 USD -1,25 USD -0,50 %
BTT
finanzen.net zero
Jazz Pharmaceuticals jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.13,63 Mrd. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1JS1K

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINIE00B4Q5ZN47

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolJAZZ

Jazz Pharmaceuticals Aktien News

DatumMeistgelesen
PR NewswireJazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025
PR NewswireJazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell ...
PR NewswireJazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ...
PR NewswireJazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated ...
PR NewswireJazz Pharmaceuticals to Participate in Upcoming June Investor Conferences
PR NewswireJazz Pharmaceuticals to Participate in Upcoming June Investor Conferences
finanzen.netJazz Pharmaceuticals: Bilanzzahlen zum vergangenen Quartal
PR NewswireJazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance
PR NewswireJazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance
finanzen.netAusblick: Jazz Pharmaceuticals legt die Bilanz zum abgelaufenen Quartal vor
PR NewswireJazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference
PR NewswireJazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference
PR NewswireJazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer
PR NewswireJazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma
PR NewswireJazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025
PR NewswireJazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025
PR NewswireJazz Pharmaceuticals Completes Acquisition of Chimerix
PR NewswireJazz Pharmaceuticals Completes Acquisition of Chimerix
PR NewswireJazz Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
PR NewswireJazz Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
PR NewswireJazz Pharmaceuticals to Showcase Research Demonstrating Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Epidiolex® (cannabidiol) at American Aca...
PR NewswireJazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
PR NewswireJazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
finanzen.netJazz Pharmaceuticals hat Bilanz für das abgelaufene Quartal gezogen
PR NewswireJazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance
PR NewswireJazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance
finanzen.netAusblick: Jazz Pharmaceuticals mit Zahlen zum abgelaufenen Quartal
PR NewswireJazz Pharmaceuticals to Participate in TD Cowen's 45th Annual Health Care Conference
PR NewswireJazz Pharmaceuticals to Participate in TD Cowen's 45th Annual Health Care Conference
PR NewswireJazz Pharmaceuticals to Report 2024 Full Year and Fourth Quarter Financial Results on February 25, 2025
PR NewswireJazz Pharmaceuticals to Report 2024 Full Year and Fourth Quarter Financial Results on February 25, 2025
PR NewswireJazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
PR NewswireJazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
PR NewswireJazz Pharmaceuticals Announces CEO Succession Plan
PR NewswireJazz Pharmaceuticals Announces CEO Succession Plan
PR NewswireJazz Pharmaceuticals to Showcase New Real-World Evidence Reinforcing Epidiolex® (cannabidiol) Benefits and Broad-Spectrum Efficacy in Treatment-Resistant Epilepsies at the American Epilepsy Societ...
PR NewswireJazz Pharmaceuticals Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii (Ziihera®)
PR NewswireJazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024
PR NewswireJazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024
PR NewswireJazz Pharmaceuticals to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting

Jazz Pharmaceuticals News

Jazz Pharmaceuticals News: auf dieser Seite finden Sie alle Jazz Pharmaceuticals News und Nachrichten zur Jazz Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Jazz Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Jazz Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.